COVID-19

COVID-19, News, Science

As Russia announces world’s first COVID vaccine, WHO says discussing prequalification

  • WHO and Russian health authorities are now discussing the process for possible WHO pre-qualification for Covid-19 vaccine
  • Russia’s first coronavirus vaccine is developed jointly by Gamaleya Research Institute and the Russian Defence Ministry
As Russia announces world's first COVID vaccine, WHO says discussing prequalification
As Russia announces world’s first COVID vaccine

Moments after Russian President Vladimir Putin announced the registration of the country’s first coronavirus vaccine, also touted as world’s first such vaccine against the virus, the World Health Organisation and Russian health authorities are now discussing the process for possible WHO prequalification for Covid-19 vaccine, a WHO spokesman said on Tuesday.

“We are in close contact with Russian health authorities and discussions are ongoing with respect to possible WHO prequalification of the vaccine, but again prequalification of any vaccine includes the rigorous review and assessment of all required safety and efficacy data,” WHO spokesman Tarik Jasarevic told a U.N. briefing in Geneva, referring to clinical trials, according to Reuters.

Russia‘s first coronavirus vaccine is developed jointly by Gamaleya Research Institute and the Russian Defence Ministry.

Clinical trials of the vaccine began on June 18 and included 38 volunteers. All of the participants developed an immunity. The first group was discharged on July 15 and the second group on July 20.

Putin’s announcement for a Covid-19 vaccine came in the wake of the novel coronavirus pandemic that has infected more than 20 million people and killed nearly 750,000 worldwide, thus, crippling world economies.

The president asked Health Minister Mikhail Murashko to keep him informed about the Covid-19 vaccine, while at the same time noting that he knows “it works quite effectively” and “forms a stable immunity”, according to Russian news agencies.

“This morning, for the first time in the world, a vaccine against the new coronavirus was registered” in Russia, Putin said during a televised video conference call with government ministers, as per news agency AFP.

Putin further thanked everyone who worked on the vaccine’s development and described it as “a very important step for the world”. He hopes the country’s research body will soon start mass production of coronavirus vaccine.

“I know that it works quite effectively, forms strong immunity, and I repeat, it has passed all the needed checks,” said Putin.

He emphasized that the vaccine underwent the necessary tests. He added that one of his two daughters has received a shot of the vaccine and is feeling well, according to Associated Press reports.

However, the vaccine’s registration is conditional and trials will continue while production gets underway, said Murashko.

Murashko also added that the first Russian vaccine against the coronavirus will begin to be produced at two sites – the Gamaleya Research Institute and the company Binnopharm.

“The two-stage injection plan helps form a lasting immunity. The experience with vector vaccines and two-stage scheme shows that immunity lasts for up to two years”, the Health Ministry said, as reported by Sputnik News.

Meanwhile, WHO had earlier said all vaccine candidates should go through full stages of testing before being rolled out.

More than 100 possible vaccines are being developed around the world to try to stop the pandemic. At least four are in final Phase III human trials, according to WHO data.

Companies including AstraZeneca Plc and Moderna Inc. are still conducting final-stage trials of their vaccines in studies that are expected to soon yield results.

Animal, COVID-19, Science

Animals Notice Something Missing at the Zoo—People

Covid closures leave some animals lonely, while others relish the peace; Row the cockatoo sings alone

chimpanzee
Animals Notice Something Missing at the Zoo—People

Humans aren’t the only ones whose routines have been upended by the pandemic.

While lockdowns have forced zoo and aquarium visitors to stay home, the animals appear to have noticed that they have the place to themselves. Some of them seem to miss people, staff say, while others don’t exactly seem to mind that no one is tapping on the glass.

COVID-19, News

Oxford COVID-19 Vaccine Shows Promise In Early Testing: Study

The immunogen failed to prompt any serious aspect effects and evoked protein and T-cell immune responses, per trial results printed within the Lancet medical journal.

Oxford COVID-19 Vaccine Shows Promise In Early Testing: Study

An experimental COVID-19 immunogen, being developed by the University of Oxford, was safe associated made an immune reaction in early-stage clinical trials in healthy volunteers, knowledge showed on a weekday.

The immunogen, known as AZD1222 and being developed by company AstraZeneca and scientists at Britain’s University of Oxford, failed to prompt any serious aspect effects and evoked protein and T-cell immune responses, per trial results printed within the Lancet medical journal.

“We hope this implies the system can bear in mind the virus, in order that our immunogen can defend folks for associate extended amount,” study lead author St. Andrew Pollard of the University of Oxford the same.

“However, we’d like a lot of analysis before we are able to ensure the immunogen effectively protects against SARS-CoV-2 (COVID-19) infection, and for the way long any protection lasts,” he same.

AstraZeneca is among the leading immunogen candidates against a scourge that has claimed quite 600,000 lives, aboard others in middle and late-stage trials.

These embody shots being developed by China’s Sinovac Biotech, another from state-owned Chinese firm Sinopharm, and one from the U.S. biotech firm Moderna.

AstraZeneca has signed agreements with governments around the world to produce the immunogen ought to prove effective and gain regulative approval. the corporate has the same it’ll not request to take advantage of the immunogen throughout the pandemic.

Researchers same the immunogen caused minor aspect effects a lot of oftentimes than an effect cluster, however, a number of these may be reduced by taking paracetamol, with no serious adverse events from the immunogen.

COVID-19, News

Russia to make coronavirus vaccine available to public next month

The vaccine will start phase 3 trials in thousands of people on 3 August in Russia as well as in Saudi Arabia and the United Arab Emirates, Dmitriev said.
 
President Vladimir Putin has made finding a vaccine a top priority.

Russia to make coronavirus vaccine available to public next month
Amid reports of the world’s first Covid-19 vaccine from Russia pouring in since the last few days, the Russian health minister said they will make a coronavirus vaccine candidate it is working on available to the general public before it clears the third and last phase of clinical trials, according to a new report.
 
“The government’s decree implies this. It will be imperative that additional clinical research of an approved vaccine be conducted simultaneously,” Murashko told reporters during a working trip to the central Russian city of Yekaterinburg, according to Sputnik News report.
 
According to a Bloomberg report, Kirill Dmitriev, the chief executive of the government-backed Russian Direct Investment Fund (RDIF), said researchers in Russia are testing two different types of adenovirus vectors in order to reduce the chances of pre-existing immunity reducing the vaccine’s effectiveness. That vaccine will start phase 3 trials in thousands of people on Aug. 3 in Russia as well as in Saudi Arabia and the United Arab Emirates, Dmitriev said. Russia could make 30 million doses domestically in 2020, and 170 million abroad, with five countries expressing interest in producing the vaccine and others willing to produce it, he said.
 
Earlier, Russia’s Sechenov University announced that it had successfully completed clinical trials of a coronavirus vaccine, developed by Russia’s Defense Ministry’s Gamalei Institute of Epidemiology and Microbiology. Alexander Lukashev, the director of Sechenov’s Institute of Medical Parasitology, Tropical and Vector-Borne Diseases, told Sputnik that the trials had established the vaccine’s safety on human health. It has recently cleared the first stage of trials in a small group of volunteers. Murashko described the outcome as “positive.”
 
 
Moreover, the research institute head also said that the Covid-19 vaccine is “patented and more advanced than Western competitors and will be happy to share the technology with foreign colleagues, should they require,” as per reports.
 
 
The statement came after the UK, the US and Canadian governments accused Russian state intelligence of hacking international research centers that are racing to develop a Covid-19 vaccine.
In a dramatic statement on Thursday, Britain’s National Cyber Security Centre (NCSC) said vaccine and therapeutic sectors in multiple countries have been targeted by a group known as APT29, which it said is “almost certainly” part of the Russian state intelligence. Security agencies in the U.S. and Canada later issued their own statements backing up the findings, reported Bloomberg.
 
However, the Kremlin has refuted the allegation.
 
“Our technology is patented, unique and with parameters which, I feel confident to claim, exceed the capabilities of analogous products being developed in the West,” Ginsburg said, adding that “most probably, if there is any borrowing, it will be our immunization scheme to be borrowed, and we will be happy to share our hacks with the colleagues, should they need.”
 
Earlier, the Russian Defence Ministry clarified that tests of the vaccine against coronavirus are being conducted in full compliance with methodological regulations, with no attempts to reduce the duration of the research.
 
“The Russian Defence Ministry tests the vaccine on volunteers in full compliance with the acting legislation and scientific methodological regulations, in order to prevent further risks, without any attempt to reduce the duration of the research”, the ministry said in a statement, as reported by Sputnik.
 
President Vladimir Putin has made finding a vaccine a top priority. Russia has recorded more than 750,000 Covid-19 cases, making it the fourth most-affected country in the world. In Russia’s race to be the first to find a vaccine against Covid-19, it’s taking an approach that would be shunned in other countries, claiming it will know in just three months of trials whether its leading candidate works.
COVID-19, News

Two coronavirus vaccines given fast-track status by US

These two experimental coronavirus vaccines have been developed by German biotech organization BioNTech and US pharmaceutical large Pfizer
Two coronavirus vaccines given fast-track status by US
The corporations had released early records from the ongoing Phase 1/2 look at on July 1
Two experimental coronavirus vaccines being developed through German biotech firm BioNTech and US pharmaceutical giant Pfizer have received the US Food and Drug Administration’s ‘rapid track’ designation. The vaccines, BNT162b1 and BNT162b2, are the maximum superior of the four vaccines being developed by using the companies. These vaccines are presently being evaluated in ongoing Phase 1/2 clinical studies in the US and Germany.
Fast Track is a technique designed to facilitate the improvement, and expedite the review, of latest capsules and vaccines that are supposed to deal with or save you serious conditions that have the potential to deal with an unmet clinical need.
Pfizer said the speedy-track repute became granted based on preliminary records from Phase half of research which can be presently ongoing inside the United States and Germany in addition to animal immunogenicity studies. The companies released early information from the continuing U.S. Phase half study for the product candidate BNT162b1 on July 1, 2020.
Early statistics from the German trial of BNT162b1 are expected to be released in July.
The BNT162 software is evaluating as a minimum of 4 experimental vaccines, every of which represents a completely unique mixture of messenger RNA (mRNA) layout and target antigen. BNT162b1 and BNT162b2 are both nucleosides changed RNAs, formulated in lipid nanoparticles. BNT162b1 encodes an optimized SARS-CoV-2 receptor-binding domain (RBD) antigen, whilst BNT162b2 encodes an optimized SARS-CoV-2 full-length spike protein antigen.
“The FDA’s choice to supply these two COVID-19 vaccine applicants Fast Track designation indicates a critical milestone inside the efforts to expand a safe and powerful vaccine against SARS-CoV-2,” said Peter Honig, Senior Vice President, Global Regulatory Affairs, Pfizer. “We stay up to preserve working closely with the FDA at some stage in the clinical improvement of this software, Project Lightspeed, to assess the protection and efficacy of these vaccine candidates.”
“We are pleased to have obtained Fast Track designation from the FDA for two of our vaccine candidates and look forward to working closely with the FDA, along with our partner Pfizer, to expedite the clinical improvement direction forward,” stated Özlem Türeci, Chief Medical Officer at BioNTech.
Subject to regulatory approval, the corporations are expecting to start a Phase 2b/3 trial as quickly as later this month and are waiting for enrolling up to 30,000 subjects. If the ongoing research is successful, and the vaccine candidate receives regulatory approval, the agencies presently count on to fabricate up to a hundred million doses via the give up of 2020 and probably more than 1.2 billion doses by way of the quit of 2021.
US President Donald Trump’s Warp Speed software has subsidized efforts at a number of agencies, inclusive of Johnson & Johnson, Novavax Inc, Merck & Co., Pfizer Inc., Moderna Inc., And AstraZeneca Plc, to get doses as early as possible.
Operation Warp Speed seeks to compress a manner that is typically years-long into a be counted of months.
Drug agencies and university researchers are investigating more than a hundred and forty experimental inoculations, in line with the World Health Organization.